Expression Levels of Nicotinamide Metabolism-related Protein (NMAP) in Newly Diagnosed Renal Cancer and Non-renal Cancer Populations

Overview

This study aims to observe the difference between NMAP (nicotinamide metabolism associated protein) serum levels in primary diagnosed renal cancer patients and non-renal cancer patient controls, plot the ROC curve and establish appropriate cut-off values.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: June 30, 2022

Interventions

  • Other: Blood test
    • About 4 ml of blood draw

Arms, Groups and Cohorts

  • Renal cancer group
    • Patients which imaging studies have found renal mass, plan to receive surgery (except for radiofrequency ablation, cryoablation, etc.), about 100.
  • Urothiasis group
    • Patients which imaging studies have found renal or ureteral stones, and rule out of renal mass, about 100.
  • Renal cysts group
    • Patients which imaging studies have found renal cysts (simple or complex) about 100.
  • Liver cancer group
    • Patients which imaging studies have found hepatic mass, plan to receive surgery (except for radiofrequency ablation, cryoablation, etc.), about 100.

Clinical Trial Outcome Measures

Primary Measures

  • NMAP level study
    • Time Frame: September 2019-September 2021
    • To observe the difference in the expression level of nicotinamide metabolism related protein (NMAP) in the serum of newly diagnosed renal cancer and non-renal cancer patients. Draw the NMAP ROC curve and establish the appropriate Cut-off value to analyze its sensitivity and specificity.

Secondary Measures

  • NMAP plus other tumor biomarkers study
    • Time Frame: September 2019-September 2021
    • According to NMAP and combined with other tumor biomarkers data such as AFP, multiple regression analysis was used to map the ROC curve and establish the appropriate Cut-off value to determine whether it is capable of distinguishing kidney cancer and liver cancer.

Participating in This Clinical Trial

Inclusion Criteria

1. The tumor group patients were found to have renal or hepatic mass, plan to receive surgical treatment (except for radiofrequency ablation, cryoablation, etc., which were not available for pathological examination). The control group patients were ruled out of tumor based on radiological tests and commonly used tumor biomarkers 2. Age ≥ 18 years old and able to provide written informed consent; 3. Have not received any systemic or topical treatment for kidney/liver tumors. 4. Cardiopulmonary, liver and kidney functions are able to tolerate surgery and can comply with research requirements. Exclusion Criteria:

1. The investigators believe that the subject may be unsuitable for inclusion due to severe concurrent diseases, infections, and etc. 2. The subjects is known or suspected of other malignancies. 3. There has been another history of malignancy in the past 5 years. 4. Major surgery (surgery requiring general anesthesia) was performed within 4 weeks prior to screening visits.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Investigator Details

  • Lead Sponsor
    • Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
  • Provider of Information About this Clinical Study
    • Principal Investigator: Jie Ding, Attending doctor – Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
  • Overall Contact(s)
    • Min NA Shi, MD, 021-25076143, shimin@xinhuamed.com.cn

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.